An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
CareDx, Inc. (NASDAQ: CDNA) has congratulated C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group for receiving European Medicine Agency's draft qualification for the iBox Scoring System, a significant step in kidney transplant trials. The iBox system evaluates graft failure risk by assessing renal function and immunologic responses. CEO Reg Seeto expressed pride in collaborating with these groups to further transplant innovation.
Positive
Receipt of European Medicine Agency draft qualification for the iBox Scoring System, enhancing its credibility in kidney transplant trials.
Negative
None.
BRISBANE, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today congratulates C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox® Scoring System as a secondary endpoint in kidney transplant clinical trials.
“CareDx congratulates C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group for receiving this regulatory approval for the iBox Scoring System. We applaud their pioneering ingenuity in customizing the iBox risk prediction scoring system for this application which is poised to have a significant impact on transplant patient lives,” said Reg Seeto, CEO and President of CareDx. “We are proud to be long-standing collaborators with the incredible teams at the Transplant Therapeutics Consortium and the Paris Transplant Group and look forward to working together to drive the next wave of transplant innovation.”
The iBox Scoring System is a composite biomarker that utilizes multiple clinically relevant patient features to fully reflect the heterogeneity of graft failure, including measures of renal function (eGFR and proteinuria) and immunologic response to the graft (donor-specific antibody), and assessment of allograft health through histopathology (Banff lesion scores).2 For more details, go here.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with iBox Scoring System, the receipt of EMA draft qualification by C-Path's Transplant Therapeutics Consortium and the Paris Transplant Group (“Receipt of Qualification”), and CareDx’s collaborations with C-Path's Transplant Therapeutics Consortium and the Paris Transplant Group (the “Collaborations”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of the ibox Scoring System and the Collaborations; risks that C-Path's Transplant Therapeutics Consortium and the Paris Transplant Group do not realize the expected benefits of the iBox Scoring System, the Receipt of Qualification, and the Collaborations; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
References
The draft qualification opinion is going through a public consultation stage through Nov. 17, 2022.
What is the significance of the iBox Scoring System for CareDx (CDNA)?
The iBox Scoring System's draft qualification by the EMA enhances its credibility, potentially improving outcomes in kidney transplant trials.
Who recognized CareDx (CDNA) for the iBox Scoring System?
CareDx congratulated C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group for gaining European Medicine Agency draft qualification.
What is CareDx's focus in the healthcare market?
CareDx specializes in clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.
When did CareDx (CDNA) announce the EMA qualification?
The announcement regarding the EMA qualification for the iBox Scoring System was made on October 27, 2022.
